Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ROP
ROP logo

ROP Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
375.990
Open
374.490
VWAP
367.77
Vol
905.29K
Mkt Cap
36.71B
Low
363.560
Amount
332.94M
EV/EBITDA(TTM)
14.55
Total Shares
100.92M
EV
46.84B
EV/OCF(TTM)
17.99
P/S(TTM)
4.82
Roper Technologies, Inc. is a diversified technology company. It operates businesses that design and develop vertical software and technology-enabled products for a variety of defensible niche markets. The Company operates through three segments: Application Software, Network Software and Technology Enabled Products. The Application Software segment includes Aderant, Clinisys, Data Innovations, Deltek, Frontline, IntelliTrans, PowerPlan, Procare, Strata, Transact/CBORD, and Vertafore. The Network Software segment includes ConstructConnect, DAT, Foundry, iPipeline, iTradeNetwork, Loadlink, MHA, SHP, and SoftWriters. The Technology Enabled Products segment includes CIVCO Medical Solutions, FMI, Inovonics, IPA, Neptune, Northern Digital, rf IDEAS, and Verathon. Aderant is a comprehensive management software solution for law and other professional services firms. Data Innovations is a software solution that enables the enterprise management of hospitals and independent laboratories.
Show More

Events Timeline

(ET)
2026-06-17
09:30:00
Roper Technologies Expands Reload Feature in Convoy Platform
select
2026-04-23 (ET)
2026-04-23
07:00:00
Roper Technologies Sees Q2 Adjusted EPS $5.25-$5.30
select
2026-04-23
07:00:00
Roper Reports Q1 Revenue of $2.1B, CEO Calls Results Strong
select
2026-04-21 (ET)
2026-04-21
09:20:00
iPipeline and Fiduciary Exchange Launch Insurance Exchange Express
select

News

Yahoo Finance
8.5
07-07Yahoo Finance
PinnedRoche Unveils New Alzheimer's Data at AAIC 2026
  • New Drug Research Progress: Roche will present five oral reports on trontinemab at the Alzheimer's Association International Conference, covering long-term data from the Phase Ib/IIa BrainshuttleTMAD study, which is expected to enhance the drug's application in early symptomatic Alzheimer's disease and solidify Roche's leadership in neurodegenerative diseases.
  • Diagnostic Test Innovation: Roche's Elecsys pTau217 blood test has received CE mark certification as a key tool for Alzheimer's diagnosis, which is anticipated to significantly improve accessibility for early detection, thereby enhancing patient diagnosis and treatment pathways to meet the urgent market demand for efficient diagnostic tools.
  • Clinical Trial Design: Roche will share the design of the PrevenTRON study for the first time, aimed at recruiting cognitively unimpaired individuals at high risk, utilizing the Elecsys pTau217 test for participant selection, marking a significant advancement in early intervention strategies for Alzheimer's disease and potentially providing new directions for future treatments.
  • Multiple Treatment Strategies: In addition to targeting amyloid with trontinemab, Roche will explore the role of the NLRP3 inflammasome in Alzheimer's disease, showcasing its potential in treating neurodegenerative disorders, further enriching its drug portfolio and enhancing market competitiveness.
NASDAQ.COM
8.0
07-07NASDAQ.COM
Analysis of ROP Dividend Expectations and Stock Performance
  • Dividend Yield Expectation: ROP's current estimated annualized dividend yield stands at 0.98%, and while dividends are often unpredictable, historical data suggests this yield may remain stable, reflecting the company's ongoing cash flow and profitability.
  • Stock Price Range: ROP's 52-week low is $305.96 and high is $571.36, with the latest trade at $371.19, indicating significant price volatility over the past year, which could impact investor confidence and decision-making.
  • ETF Holding Proportion: ROP constitutes 6.96% of the Akre Focus ETF, which is trading up about 1.4% on the day, suggesting that ROP's performance significantly influences the overall performance of the ETF, potentially attracting more investor attention.
  • Intraday Trading Performance: On Tuesday, Roper Technologies Inc shares rose approximately 2.4%, reflecting market optimism regarding its future performance, likely linked to its stable dividend policy and strong financial health.
Yahoo Finance
9.0
07-02Yahoo Finance
Roche's Krascendo 1 Study Shows Promising Potential for New Drug
  • Clinical Trial Success: Roche's Krascendo 1 study demonstrates that divarasib significantly improves progression-free survival (PFS) and overall survival (OS) in previously treated patients with KRAS G12C non-small cell lung cancer compared to existing KRAS G12C inhibitors, indicating its potential to become a new standard of care.
  • Safety Profile: The safety profile of divarasib remained consistent with previous data, with no new safety signals observed, and the most common treatment-related events were manageable and reversible, ensuring patient safety during treatment.
  • Urgent Market Need: The KRAS G12C mutation is one of the most common mutations in non-small cell lung cancer, found in approximately 14% of cases, highlighting a significant unmet need for effective treatments, which divarasib could potentially address.
  • Future Development Plans: Roche is advancing a comprehensive clinical development program for divarasib, investigating its efficacy across different disease stages and lines of therapy, aiming to bring this promising treatment option to market as soon as possible.
Newsfilter
7.5
06-29Newsfilter
U.S. Bank Freight Payment Index Reports Surge in Freight Rates
  • Freight Rates Surge: The latest U.S. Bank Freight Payment Index indicates a significant rise in dry van rates, with spot rates increasing by 31.29% year-over-year in May, reflecting a notable acceleration over recent months.
  • Contract Rate Growth: Contract rates also showed an upward trend, rising from $2.09 per mile in March to $2.18 in May, marking a 9% year-over-year increase, indicating sustained demand for capacity in the market.
  • Decline in Shipment Activity: Despite rising rates, shipment activity declined throughout the quarter, with spot volumes dropping from approximately 1.36 million in March to 1.11 million in May, and contract volumes decreasing by 13.3%, signaling signs of softening demand.
  • Market Adjustment Recommendations: Jeff Pape, Head of Transportation at U.S. Bank, emphasized that despite lower volumes, costs are rising rapidly, advising shippers to adjust their budgets according to these new higher baselines to avoid risks associated with outdated cost assumptions.
Newsfilter
5.0
06-25Newsfilter
DAT Launches Load Recommendations Feature in DAT One App
  • Feature Launch: DAT Freight & Analytics has introduced the Load Recommendations feature in its mobile app, designed to enhance carrier efficiency by providing tailored load suggestions that fit their trucks and operational preferences, thereby reducing time spent searching for loads.
  • Intelligent Recommendation System: This feature utilizes factors such as carrier equipment types, typical lanes, and engagement patterns within the DAT One marketplace to automatically prioritize loads that align with their operational patterns, ensuring quick access to desirable loads.
  • Mobile-First Design: Load Recommendations is specifically designed for carriers operating from their cabs, delivering a more relevant set of loads to review, which minimizes time spent on filtering and comparing, allowing carriers to focus more on hauling.
  • User-Friendly Approach: The feature is intended as a faster starting point rather than a replacement for carrier judgment, as users retain full access to traditional search options, ensuring a comprehensive user experience beyond the recommendations.
Newsfilter
7.5
06-17Newsfilter
Chartwell Law Adopts Aderant Expert Sierra to Enhance Operational Efficiency
  • Cloud Management Platform: Chartwell Law's adoption of Aderant Expert Sierra, a cloud-based practice and financial management platform, positions it as a cloud-first law firm, enhancing scalability and security to support rapid nationwide growth.
  • Efficiency Gains: By eliminating reliance on fragmented systems and automating workflows, Expert Sierra enables Chartwell Law to accelerate work-to-cash cycles and maximize profitability, which is expected to significantly enhance ROI for both attorneys and management.
  • Real-Time Visibility: The new platform provides attorneys with real-time access to billing, timekeeping, and matter management tools, streamlining daily tasks and improving client service, while offering leadership a single source of truth for firmwide operations to facilitate faster decision-making.
  • AI Investment Strategy: The adoption of Expert Sierra is part of Chartwell Law's broader investment in AI and custom development, aiming to build a modern integration and automation layer in collaboration with technology partners like Aderant, enhancing data quality and responsive reporting to create a scalable foundation for future AI-driven capabilities.
Wall Street analysts forecast ROP stock price to rise
15 Analyst Rating
Wall Street analysts forecast ROP stock price to rise
10 Buy
2 Hold
3 Sell
Moderate Buy
Current: 0.000
sliders
Low
419.00
Averages
558.36
High
650.00
Current: 0.000
sliders
Low
419.00
Averages
558.36
High
650.00
RBC Capital
Sector Perform
maintain
$393 -> $407
AI Analysis
2026-04-24
Reason
RBC Capital
Price Target
$393 -> $407
AI Analysis
2026-04-24
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Roper Technologies to $407 from $393 and keeps a Sector Perform rating on the shares. The company reported a modest Q1 earnings beat and raised guidance on improved application software margins, the analyst tells investors in a research note. RBC also cites the company noting progress on AI product commercialization though many initiatives remain nascent.
Baird
Outperform
maintain
$464 -> $470
2026-04-24
Reason
Baird
Price Target
$464 -> $470
2026-04-24
maintain
Outperform
Reason
Baird raised the firm's price target on Roper Technologies to $470 from $464 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ROP
Unlock Now

Valuation Metrics

The current forward P/E ratio for Roper Technologies Inc (ROP.O) is 16.78, compared to its 5-year average forward P/E of 27.44. For a more detailed relative valuation and DCF analysis to assess Roper Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
27.44
Current PE
16.78
Overvalued PE
31.13
Undervalued PE
23.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
21.11
Current EV/EBITDA
13.81
Overvalued EV/EBITDA
24.38
Undervalued EV/EBITDA
17.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.43
Current PS
4.04
Overvalued PS
8.76
Undervalued PS
6.10

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what are the Helium stocks available
Intellectia · 27 candidates
Themes: Industrial
Ticker
Name
Market Cap$
top bottom
CAT logo
CAT
Caterpillar Inc
413.36B
GE logo
GE
General Electric Co
310.03B
BA logo
BA
Boeing Co
187.11B
ETN logo
ETN
Eaton Corporation PLC
155.91B
DE logo
DE
Deere & Co
155.27B
HON logo
HON
Honeywell International Inc
135.04B
STOCK PICKS
Intellectia · 51 candidates
Market Cap: >= 10.00BNet Margin: >= 8.00Beta: ModerateRiskRevenue 5yr Cagr: >= 5.00Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
GOOG logo
GOOG
Alphabet Inc
3.60T
MSFT logo
MSFT
Microsoft Corp
2.77T
MS logo
MS
Morgan Stanley
263.38B
GS logo
GS
Goldman Sachs Group Inc
255.48B
AXP logo
AXP
American Express Co
209.66B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
124.46B
what stock should i buy with 12k
Intellectia · 48 candidates
Market Cap: >= 10.00BRegion: USNet Margin: >= 10.00Beta: ModerateRiskRevenue 5yr Cagr: >= 5Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MS logo
MS
Morgan Stanley
251.50B
GS logo
GS
Goldman Sachs Group Inc
236.85B
AXP logo
AXP
American Express Co
200.43B
NVO logo
NVO
Novo Nordisk A/S
160.92B
BLK logo
BLK
BlackRock Inc
145.25B
PDD logo
PDD
PDD Holdings Inc
141.69B
what stock should I buy
Intellectia · 91 candidates
Region: USAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 35List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
AMZN logo
AMZN
Amazon.com Inc
2.20T
HST logo
HST
Host Hotels & Resorts Inc
12.79B
UBER logo
UBER
Uber Technologies Inc
152.07B
GM logo
GM
General Motors Co
65.82B
RSG logo
RSG
Republic Services Inc
67.72B
LVS logo
LVS
Las Vegas Sands Corp
35.56B
what stocks should I buy on Monday?
Intellectia · 9 candidates
Rsi Category: moderateEps 5yr Cagr: >= 10Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
476.92B
SCHW logo
SCHW
Charles Schwab Corp
165.86B
OKE logo
OKE
ONEOK Inc
56.18B
ROP logo
ROP
Roper Technologies Inc
36.40B
FOXA logo
FOXA
Fox Corp
24.60B
NTAP logo
NTAP
NetApp Inc
19.95B
what other stocks should I buy and why
Intellectia · 14 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
PTC logo
PTC
PTC Inc
19.39B
MSFT logo
MSFT
Microsoft Corp
3.01T
NVO logo
NVO
Novo Nordisk A/S
171.90B
SEIC logo
SEIC
SEI Investments Co
10.00B
BMRN logo
BMRN
BioMarin Pharmaceutical Inc
11.62B
BR logo
BR
Broadridge Financial Solutions Inc
22.04B
je veux trader sur le nasdaq 100
Intellectia · 16 candidates
Price: $10.00 - $500.00Analyst Consensus: Strong Buy, Moderate BuyBeta: ModerateRiskIs Index Component: NDX
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.76T
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
NFLX logo
NFLX
Netflix Inc
324.56B
ISRG logo
ISRG
Intuitive Surgical Inc
172.54B
PDD logo
PDD
PDD Holdings Inc
142.36B
what stocks to buy
Intellectia · 26 candidates
Market Cap: >= 30.00BAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5Target Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
TEAM logo
TEAM
Atlassian Corp
35.80B
NOW logo
NOW
ServiceNow Inc
140.56B
CRM logo
CRM
Salesforce Inc
216.10B
ADBE logo
ADBE
Adobe Inc
123.59B
WDAY logo
WDAY
Workday Inc
50.46B
KKR logo
KKR
KKR & Co Inc
105.48B
stocks that has below 40 rsi
Intellectia · 221 candidates
Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.64T
MSFT logo
MSFT
Microsoft Corp
3.30T
MA logo
MA
Mastercard Inc
473.76B
NFLX logo
NFLX
Netflix Inc
361.70B
CRM logo
CRM
Salesforce Inc
207.62B
TMUS logo
TMUS
T-Mobile US Inc
205.36B
oversold stocks
Intellectia · 84 candidates
Market Cap: >= 1000.00MRsi Category: oversoldWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.64T
MSFT logo
MSFT
Microsoft Corp
3.30T
MA logo
MA
Mastercard Inc
473.76B
NFLX logo
NFLX
Netflix Inc
361.70B
CRM logo
CRM
Salesforce Inc
207.62B
TMUS logo
TMUS
T-Mobile US Inc
205.36B

Whales Holding ROP

E
Eventide Asset Management, LLC
Holding
ROP
+33.34%
3M Return
D
D. E. Shaw & Co., L.P.
Holding
ROP
+19.27%
3M Return
A
Applied Finance Advisors, LLC
Holding
ROP
+19.26%
3M Return
I
Inspire Investing, LLC
Holding
ROP
+16.46%
3M Return
P
ProShare Advisors LLC
Holding
ROP
+14.48%
3M Return
Z
ZWJ Investment Counsel Inc
Holding
ROP
+13.96%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Roper Technologies Inc (ROP) stock price today?

The current price of ROP is 363.76 USD — it has decreased -0.13

What is Roper Technologies Inc (ROP)'s business?

Roper Technologies, Inc. is a diversified technology company. It operates businesses that design and develop vertical software and technology-enabled products for a variety of defensible niche markets. The Company operates through three segments: Application Software, Network Software and Technology Enabled Products. The Application Software segment includes Aderant, Clinisys, Data Innovations, Deltek, Frontline, IntelliTrans, PowerPlan, Procare, Strata, Transact/CBORD, and Vertafore. The Network Software segment includes ConstructConnect, DAT, Foundry, iPipeline, iTradeNetwork, Loadlink, MHA, SHP, and SoftWriters. The Technology Enabled Products segment includes CIVCO Medical Solutions, FMI, Inovonics, IPA, Neptune, Northern Digital, rf IDEAS, and Verathon. Aderant is a comprehensive management software solution for law and other professional services firms. Data Innovations is a software solution that enables the enterprise management of hospitals and independent laboratories.

What is the price predicton of ROP Stock?

Wall Street analysts forecast ROP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROP is558.36 USD with a low forecast of 419.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Roper Technologies Inc (ROP)'s revenue for the last quarter?

Roper Technologies Inc revenue for the last quarter amounts to 2.10B USD, increased 11.29

What is Roper Technologies Inc (ROP)'s earnings per share (EPS) for the last quarter?

Roper Technologies Inc. EPS for the last quarter amounts to 4.87 USD, increased 59.15

How many employees does Roper Technologies Inc (ROP). have?

Roper Technologies Inc (ROP) has 19400 emplpoyees as of July 08 2026.

What is Roper Technologies Inc (ROP) market cap?

Today ROP has the market capitalization of 36.71B USD.